Keyword: Fresenius Kabi

With hundreds of drug shortages hitting the pharmaceutical industry each quarter, Merck KGaA is hoping a novel machine-learning platform will help.

Swine fever in China has forced one of the largest manufacturers of heparin to begin limiting allocations of the treatment.

Fresenius Kabi missed an opportunity to quickly bulk up in sterile manufacturing when its $5 billion deal to buy Akorn imploded last year.

Just weeks after being hit with an FDA letter for its Illinois manufacturing operations, the FDA tagged a different Akorn plant with a Form 483.

Following a handful of deals for other biosimilar drugmakers, Pfizer decided to settle its Humira patent fight with AbbVie.

Fresenius recalls 163 lots of sodium chloride, the CEO of MHRA is leaving, plus other manufacturing news.

The FDA issued a 22-page, 11-observation Form 483 to Akorn’s Parsippany, New Jersey, plant following a five-week inspection.

In a Humira patent deal with AbbVie, Fresenius Kabi will have to pay undisclosed royalties and can launch its biosim in Europe upon approval.

Fresenius continues to hammer Akorn with fraud allegations as the company tries to extract itself from a $4.3 billion buyout of the injectables maker.

Fresenius’ $4.3 billion buyout of generics maker Akorn is in jeopardy as they investigate allegations that Akorn violated FDA drug development standards.